250 related articles for article (PubMed ID: 29443653)
1. Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial.
Wapnir IL; Price KN; Anderson SJ; Robidoux A; Martín M; Nortier JWR; Paterson AHG; Rimawi MF; Láng I; Baena-Cañada JM; Thürlimann B; Mamounas EP; Geyer CE; Gelber S; Coates AS; Gelber RD; Rastogi P; Regan MM; Wolmark N; Aebi S; ; ;
J Clin Oncol; 2018 Apr; 36(11):1073-1079. PubMed ID: 29443653
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial.
Aebi S; Gelber S; Anderson SJ; Láng I; Robidoux A; Martín M; Nortier JW; Paterson AH; Rimawi MF; Cañada JM; Thürlimann B; Murray E; Mamounas EP; Geyer CE; Price KN; Coates AS; Gelber RD; Rastogi P; Wolmark N; Wapnir IL;
Lancet Oncol; 2014 Feb; 15(2):156-63. PubMed ID: 24439313
[TBL] [Abstract][Full Text] [Related]
3. Poor Prognosis After Second Locoregional Recurrences in the CALOR Trial.
Wapnir IL; Gelber S; Anderson SJ; Mamounas EP; Robidoux A; Martín M; Nortier JW; Geyer CE; Paterson AH; Láng I; Price KN; Coates AS; Gelber RD; Rastogi P; Regan MM; Wolmark N; Aebi S;
Ann Surg Oncol; 2017 Feb; 24(2):398-406. PubMed ID: 27663567
[TBL] [Abstract][Full Text] [Related]
4. Association between the 21-gene recurrence score and isolated locoregional recurrence in stage I-II, hormone receptor-positive breast cancer.
Yang DD; Buscariollo DL; Cronin AM; Weng S; Hughes ME; Bleicher RJ; Cohen AL; Javid SH; Edge SB; Moy B; Niland JC; Wolff AC; Hassett MJ; Punglia RS
Radiat Oncol; 2020 Aug; 15(1):198. PubMed ID: 32799886
[TBL] [Abstract][Full Text] [Related]
5. 21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy.
Mamounas EP; Liu Q; Paik S; Baehner FL; Tang G; Jeong JH; Kim SR; Butler SM; Jamshidian F; Cherbavaz DB; Sing AP; Shak S; Julian TB; Lembersky BC; Wickerham DL; Costantino JP; Wolmark N
J Natl Cancer Inst; 2017 Jan; 109(4):. PubMed ID: 28122895
[TBL] [Abstract][Full Text] [Related]
6. Effect of adjuvant chemotherapy in patients with ER + /HER2- breast cancer, assessed by propensity score matching: significance of nuclear grade and nodal status.
Tanaka N; Hirano A; Hattori A; Ogura K; Kamimura M; Inoue H; Yukawa H; Sakaguchi S; Matsuoka A; Kodera A; Shimizu T
Breast Cancer; 2021 Jan; 28(1):40-47. PubMed ID: 32592141
[TBL] [Abstract][Full Text] [Related]
7. Therapy of isolated locoregional recurrent carcinoma of the breast.
Gabriel L; Schmidt M; Juhasz-Böss S; Melchior P; von Heesen A; Schmidt G; Kranzhöfer N; Solomayer EF; Juhasz-Böss I; Breitbach GP
Arch Gynecol Obstet; 2019 Aug; 300(2):365-376. PubMed ID: 31222400
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial.
Toi M; Imoto S; Ishida T; Ito Y; Iwata H; Masuda N; Mukai H; Saji S; Shimizu A; Ikeda T; Haga H; Saeki T; Aogi K; Sugie T; Ueno T; Kinoshita T; Kai Y; Kitada M; Sato Y; Jimbo K; Sato N; Ishiguro H; Takada M; Ohashi Y; Ohno S
Lancet Oncol; 2021 Jan; 22(1):74-84. PubMed ID: 33387497
[TBL] [Abstract][Full Text] [Related]
9. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343.
Hughes KS; Schnaper LA; Bellon JR; Cirrincione CT; Berry DA; McCormick B; Muss HB; Smith BL; Hudis CA; Winer EP; Wood WC
J Clin Oncol; 2013 Jul; 31(19):2382-7. PubMed ID: 23690420
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomized trial (SAKK 23/82) comparing tamoxifen with observation.
Waeber M; Castiglione-Gertsch M; Dietrich D; Thürlimann B; Goldhirsch A; Brunner KW; Borner MM;
Ann Oncol; 2003 Aug; 14(8):1215-21. PubMed ID: 12881382
[TBL] [Abstract][Full Text] [Related]
11. Biological Subtype Predicts Risk of Locoregional Recurrence After Mastectomy and Impact of Postmastectomy Radiation in a Large National Database.
Tseng YD; Uno H; Hughes ME; Niland JC; Wong YN; Theriault R; Blitzblau RC; Moy B; Breslin T; Edge SB; Hassett MJ; Punglia RS
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):622-30. PubMed ID: 26461004
[TBL] [Abstract][Full Text] [Related]
12. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
[TBL] [Abstract][Full Text] [Related]
13. Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05).
Blok EJ; Kroep JR; Meershoek-Klein Kranenbarg E; Duijm-de Carpentier M; Putter H; van den Bosch J; Maartense E; van Leeuwen-Stok AE; Liefers GJ; Nortier JWR; Rutgers EJT; van de Velde CJH;
J Natl Cancer Inst; 2018 Jan; 110(1):. PubMed ID: 28922787
[TBL] [Abstract][Full Text] [Related]
14. Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy.
Abdulkarim BS; Cuartero J; Hanson J; Deschênes J; Lesniak D; Sabri S
J Clin Oncol; 2011 Jul; 29(21):2852-8. PubMed ID: 21670451
[TBL] [Abstract][Full Text] [Related]
15. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcome of isolated locoregional recurrence in patients with breast cancer according to their primary local treatment.
Shenouda MN; Sadek BT; Goldberg SI; Keruakous AR; Croft BJ; Abi Raad RF; Taghian AG
Clin Breast Cancer; 2014 Jun; 14(3):198-204. PubMed ID: 24485702
[TBL] [Abstract][Full Text] [Related]
17. Risk stratification system for groups with a low, intermediate, and high risk of subsequent distant metastasis and death following isolated locoregional recurrence of breast cancer.
Lee YJ; Park H; Kang CM; Gwark SC; Lee SB; Kim J; Chung IY; Ko BS; Kim HJ; Kim SB; Ahn SD; Gong G; Son BH; Ahn SH; Lee JW
Breast Cancer Res Treat; 2020 Jan; 179(2):315-324. PubMed ID: 31642987
[TBL] [Abstract][Full Text] [Related]
18. The variation and clinical significance of hormone receptors and Her-2 status from primary to metastatic lesions in breast cancer patients.
Zhu YY; Si W; Ji TF; Guo XQ; Hu Y; Yang JL
Tumour Biol; 2016 Jun; 37(6):7675-84. PubMed ID: 26687919
[TBL] [Abstract][Full Text] [Related]
19. A prediction model for distant metastasis after isolated locoregional recurrence of breast cancer.
Murata T; Yoshida M; Shiino S; Ogawa A; Watase C; Satomi K; Jimbo K; Maeshima A; Iwamoto E; Takayama S; Suto A
Breast Cancer Res Treat; 2023 May; 199(1):57-66. PubMed ID: 36869991
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
